Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children

References

• Masomian M, Ahmad Z, Gew LT, et al. Development of next generation streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel). 2020 Mar 17;8(1):132. doi: 10.3390/vaccines8010132
   PubMed Web of Science ®Google Scholar
• Scelfo C, Menzella F, Fontana M, et al. Pneumonia and invasive pneumococcal diseases: The role of pneumococcal conjugate vaccine in the era of multi-drug resistance. Vaccines (Basel). 2021 Apr 22;9(5):420. doi: 10.3390/vaccines9050420
   PubMed Web of Science ®Google Scholar
• Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (pcv15) in healthy infants. Vaccine. 2018 Oct 29;36(45):6883–6891. eng. doi: 10.1016/j.vaccine.2018.02.113.
   PubMed Web of Science ®Google Scholar
• Platt HL, Greenberg D, Tapiero B, et al. A phase ii trial of safety, tolerability and immunogenicity of v114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020 Aug;39(8):763–770. eng. doi: 10.1097/INF.0000000000002765
   PubMed Web of Science ®Google Scholar
• Sobanjo-Ter Meulen A, Vesikari T, Malacaman EA, et al. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal Query. 2015 Feb;34(2):186–94. eng. doi: 10.1097/INF.0000000000000516
   PubMed Web of Science ®Google Scholar
• A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infant. Eudract no. 2019-003305-10 [cited 2023 Jun 26]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003305-10/results
   Google Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of streptococcus pneumoniae causing invasive disease in children in the post-pcv era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi: 10.1371/journal.pone.0177113
   PubMed Web of Science ®Google Scholar
• Kandasamy R, Voysey M, Collins S, et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020 Mar 28;221(8):1361–1370. doi: 10.1093/infdis/jiz178
   PubMed Web of Science ®Google Scholar
• Rockett RJ, Oftadeh S, Bachmann NL, et al. Genome-wide analysis of streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in australia. Sci Rep. 2018 Nov 16;8(1):16969. doi: 10.1038/s41598-018-35270-1
   PubMed Web of Science ®Google Scholar
• Adebanjo TA, Pondo T, Yankey D, et al. Pneumococcal conjugate vaccine breakthrough infections: 2001-2016. Pediatrics. 2020 Mar;145(3). doi: 10.1542/peds.2019-0836
   PubMed Web of Science ®Google Scholar
• Mungall BA, Hoet B, Nieto Guevara J, et al. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022 Feb;21(2):201–214. eng. doi: 10.1080/14760584.2022.2012455
   PubMed Web of Science ®Google Scholar
• Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020 Apr;26(4):512 e1–512 e10. doi: 10.1016/j.cmi.2019.09.008
   PubMed Web of Science ®Google Scholar
• Hu T, Weiss T, Bencina G, et al. Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines. J Med Econ. 2021 Jan;24(1):1083–1086. doi: 10.1080/13696998.2021.1970974
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010 Sep;126(3):e493–505. doi: 10.1542/peds.2009-3027
   PubMed Web of Science ®Google Scholar
• Rid A, Saxena A, Baqui AH, et al. Placebo use in vaccine trials: recommendations of a who expert panel. Vaccine. 2014 Aug 20;32(37):4708–4712. doi: 10.1016/j.vaccine.2014.04.022
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series 9272005.
   Google Scholar
• Ryman J, Weaver J, Hu T, et al. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. NPJ Vaccines. 2022 Nov 7;7(1):140. doi: 10.1038/s41541-022-00538-1
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007 May 10;25(19):3816–3826. doi: 10.1016/j.vaccine.2007.01.119
   PubMed Web of Science ®Google Scholar
• Ryman J, Weaver J, Yee KL, et al. Predicting effectiveness of the v114 vaccine against invasive pneumococcal disease in children. Expert Rev Vaccines. 2022 Oct;21(10):1515–1521. doi: 10.1080/14760584.2022.2112179
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: A matched case-control study. Lancet. 2006 Oct 28;368(9546):1495–1502. doi: 10.1016/S0140-6736(06)69637-2
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016 May;4(5):399–406. doi: 10.1016/S2213-2600(16)00052-7
   PubMed Web of Science ®Google Scholar
• A study to evaluate the safety, tolerability, and immunogenicity of two lots of v114 in healthy infants (v114-008). Clinicaltrials.Gov id: Nct02987972]. [cited 2022 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02987972
   Google Scholar
• A study to evaluate the interchangeability of v114 and Prevnar 13™ in healthy infants (v114-027/pneu-direction). [Clinicaltrials.Gov id: Nct03620162]. [cited 2022 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT03620162
   Google Scholar
• Safety, tolerability, and immunogenicity of v114 in healthy infants (v114-029) ( pneu-ped). Clinicaltrials.Gov id: Nct03893448. [cited 2022 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT03893448
   Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014 Sep;14(9):839–846. doi: 10.1016/S1473-3099(14)70822-9
   PubMed Web of Science ®Google Scholar
• Mussi-Pinhata MM, Ward S, Laimon L, et al. Effect of maternal immunization with 10-valent pneumococcus conjugate vaccine (pcv-10), 23-valent pneumococcus polysaccharide vaccine, or placebo on the immunogenicity of pcv-10 in human immunodeficiency virus-exposed uninfected infants: a randomized clinical trial. Clin Infect Dis. 2022 Sep 29;75(6):996–1005. doi: 10.1093/cid/ciac026
   PubMed Web of Science ®Google Scholar
• A study of v419 given concomitantly with Prevnar 13™ and rotateq™ (p. v419–006). Clinicaltrials.Gov id: Nct01340937. [cited 2022 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT01340937
   Google Scholar
• Nolan KM, Zhang Y, Antonello JM, et al. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the who reference elisa. Bioanalysis. 2020 Oct;12(19):1363–1375. doi: 10.4155/bio-2020-0023
   PubMed Web of Science ®Google Scholar
• Tan CY, Immermann FW, Sebastian S, et al. Evaluation of a validated luminex-based multiplex immunoassay for measuring immunoglobulin g antibodies in serum to pneumococcal capsular polysaccharides. mSphere. 2018 Aug 8;3(4):e00127–18. eng. doi: 10.1128/mSphere.00127-18
   PubMed Web of Science ®Google Scholar
• de Miguel S, Domenech M, Gonzalez-Camacho F, et al. Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era. Clin Infect Dis. 2021 Dec 6;73(11):e3778–e3787. doi: 10.1093/cid/ciaa1483
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018 Apr;18(4):441–451. doi: 10.1016/S1473-3099(18)30052-5
   PubMed Web of Science ®Google Scholar
• Zintgraff J, Gagetti P, Napoli D, et al. Invasive streptococcus pneumoniae isolates from pediatric population in Argentina for the period 2006-2019. Temporal progression of serotypes distribution and antibiotic resistance. Vaccine. 2022 Jan 24;40(3):459–470. doi: 10.1016/j.vaccine.2021.12.008
   PubMed Web of Science ®Google Scholar
• Nanduri SA, Petit S, Smelser C, et al. Epidemiology of invasive early-onset and late-onset group b streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance. JAMA Pediatr. 2019 Mar 1;173(3):224–233. doi: 10.1001/jamapediatrics.2018.4826
   PubMed Web of Science ®Google Scholar
• De Miguel S, Latasa P, Yuste J, et al. Age-dependent serotype-associated case-fatality rate in invasive pneumococcal disease in the autonomous community of Madrid between 2007 and 2020. Microorganisms. 2021 Nov 3;9(11):2286. doi: 10.3390/microorganisms9112286
   PubMed Web of Science ®Google Scholar
• Lapidot R, Shea KM, Yildirim I, et al. Characteristics of serotype 3 invasive pneumococcal disease before and after universal childhood immunization with pcv13 in massachusetts. Pathogens. 2020 May 21;9(5):396. doi: 10.3390/pathogens9050396
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Gierke R, Farley M, et al. Epidemiology of invasive pneumococcal disease (ipd) following 18 years of pneumococcal conjugate vaccine (pcv) use in the United States. Open Forum Infect Dis. 2020;7(Supplement 1):S736–S737. doi: 10.1093/ofid/ofaa439.1651
   Google Scholar